Forms of a compound of pirrolocarbazol merged, that include the compositions and their use in the treatment of Solid tumors and angiogenesis.

摘要

1. Solid and / or chemical alternative forms and compositions of compound 1. Claim 1: crystalline form of compound 1 (11 isobutyl 2 methyl 8 - (2 pyridine toluene) - 2,5,6,11,12,13-hexahydro-4h-indazolo [5,4-a] pyridine [3,4-c] carbazol-4-ona. 2. Claim 2: the crystal form of claim 1 is ptsa-a1. Requirement 3: crystal form conforming to requirement 2, and its X-ray powder diffraction characteristics include one or more of the following peaks: 5.37ml 0.2degree 2-theta 6.79ml 0.2degree 2-theta, 13.64ml 0.2degree 2-theta,22.58 ñ 0.2 degrees 2-theta and / or 25.54 ñ 0.2 degrees 2-theta, when measured using Cu-K alpha radiation (lambda = 1.54056 A). Claim 8: A crystalline form according to claim 1, wherein the crystalline form is Form pTSA-A2. Claim 9: A crystalline form according to claim 8 having an X-ray powder diffraction pattern comprising one or more of the following peaks: 5.63 ñ 0.2 degrees 2-theta, 8.48 ñ 0 , 2 degrees 2-theta, 12.46 ñ 0.2 degrees 2-theta, 18.21 + 0.2 degrees 2-theta and / or 23.95 ñ 0.2 degrees 2-theta,when measured using Cu-Ka radiation (lambda = 1,54056 A). Claim 14: A crystalline form according to claim 1, wherein the crystalline form is Formula A0. Claim 15: A crystalline form according to claim 14 having an X-ray powder diffraction pattern comprising one or more of the following peaks: 6.70 ñ 0.2 degrees 2-theta, 7.00 ñ 0 , 2 degrees 2-theta, 8.19 + 0.2 degrees 2-theta, 13.69 ñ 0.2 degrees 2-theta and / or 24.27 ñ 0.2 degrees 2-theta, when measured using radiation Cu-Ka (lambda = 1,54056 A).